Failing to cover Alzheimer’s therapies a costly proposition: researchers
By
Kimberly Bonvissuto
Jun 16, 2023
Not managing Alzheimer’s disease and related dementias is a costly proposition not just to families, but also to society, according to two recent studies.
Telemedicine increases access to care for assisted living residents with dementia: study
By
Kimberly Bonvissuto
May 30, 2023
Although racial/ethnic and socioeconomically disadvantaged populations were less likely to use telemedicine early in the COVID-19 pandemic, a new study finds that telemedicine offered a way for members...
Lawmakers turn up heat on CMS to expand access to Alzheimer’s treatments
By
Kimberly Bonvissuto
Apr 28, 2023
Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...
‘Alzheimer’s crisis’ intersecting with direct care workforce challenges, association says
By
Kimberly Bonvissuto
Mar 16, 2023
The nation is facing an “Alzheimer’s crisis” as the number of older adults in whom the disease is diagnosed continues to increase amid a shortage of direct care workers, according to the Alzheimer’s...
Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Advocates ‘appalled’ as CMS again says it will not cover monoclonal antibody treatments for Alzheimer’s
By
Kimberly Bonvissuto
Feb 24, 2023
Advocates of those living with Alzheimer’s disease are expressing disappointment that the Centers for Medicare & Medicaid Services on Wednesday rejected a request to expand its coverage of monoclonal...
Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Decision-making on antipsychotic medication use in assisted living needs system-level perspective: study
By
Kimberly Bonvissuto
Jan 25, 2023
Decisions on administering as-needed antipsychotic medications in assisted living/ residential care communities are based on attitudes, underlying morality and perceived expertise, requiring a system-level...
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.